← Back to headlines
MannKind Corporation Stock Up 20% Post-FDA Approval
MannKind Corporation (MNKD) has seen its stock price increase by 20% following the FDA approval of its product, Afrezza. This surge reflects positive market reaction to the regulatory milestone.
9 Jul, 17:29 — 9 Jul, 17:29
Sources
Showing 1 of 1 sources
Related Stories
Meta, States Have Discussed Settling Teen Social Media Harm Case
14m ago
SpaceX plans to build the ‘biggest launch site on Earth’ for $100 billion in Louisiana - CNN
22m ago
Japan's Corporate Services Inflation Accelerates in July
28m ago
Multiple Company Executives Sell Shares in Various Transactions
1h ago